单选题Companies have embarked on what looks like the beginnings of a re-run of the mergers and acquisitions (M&A) wave that defined the second bubbly half of the 1990s. That period, readers might recall, was characterized by a collective splurge that saw the creation of some of the most indebted companies in history, many of which later went bankrupt or were themselves broken up. Wild bidding for telecoms, internet and media assets, not to mention the madness that was Daimler's $40 billion motoring takeover in 1998-1999 of Chrysler or the Time-Warner/AOL mega-merger in 2000, helped to give mergers a thoroughly bad name. A consensus emerged that M&A was a great way for investment banks to reap rich fees, and a sure way for ambitious managers to betray investors by trashing the value of their shares. Now M&A is back. Its return is a global phenomenon, but it is perhaps most striking in Europe, where so far this year there has been a stream of deals worth more than $600 billion in total, around 40% higher than in the same period of 2004. The latest effort came this week when France's Saint-Gobain, a building-materials firm, unveiled the details of its￡3.6 billion ($6.5 billion) hostile bid for BPB, a British rival. In the first half of the year, cross-border activity was up threefold over the same period last year. Even France Telecom, which was left almost bankrupt at the end of the last merger wave, recently bought Amena , a Spanish mobile operator. Shareholder's approval of all these deals raises an interesting question for companies everywhere, are investors right to think that these mergers are more likely to succeed than earlier ones? There are two answers. The first is that past mergers may have been judged too harshly. The second is that the present rash of European deals does look more rational, but-and the caveat is crucial-only so far. The pattern may not hold. M&A 's poor reputation stems not only from the string of spectacular failures in the 1990s, but also from studies that showed value destruction for acquiring shareholders in 80% of deals. But more recent studies by economists have introduced a note of caution. Investors should look at the number of deals that succeed or fail (typically measured by the impact on the share price), rather than (as you might think) weighing them by size. For example, no one doubts that the Daimler-Chrysler merger destroyed value. The combined market value of the two firms is still below that of Daimler alone before the deal. This single deal accounted for half of all German M&A activity by value in 1998 and 1999, and probably dominated people's thinking about mergers to the same degree. Throw in a few other such monsters and it is no wonder that broad studies have tended to find that mergers are a bad idea. The true picture is more complicated.

单选题 对原因未明的急性口服中毒的病人，洗胃液采用 A、20～40g/L鞣酸 B、1：5000高锰酸钾 C、20g/L碳酸氢钠 D、生理盐水或清水 E、茶叶水

单选题某老年呼吸衰竭病人，近日因咳嗽、咳痰、气急明显，又出现神志不清、发绀、多汗及皮肤湿润温暖。查血气分析，pH7.3，PaO245mmHg，PaCO280mmHg，应给予（ ）

单选题A．呼吸性支气管呈囊状扩张B．肺泡管、肺泡囊和肺泡扩张C．二者均有D．二者均无 (1989年)

单选题 当血清钙浓度超过多少时，甲状旁腺功能亢进症患者容易出现神经系统症状 ( ) A、1mmol/L B、1.25mmol/L C、2.25mmol/L D、2.75mmol/L E、3mmol/L

单选题哪项是二尖瓣狭窄伴心房颤动患者最常见的并发症( )(2006年)

单选题下列关于肺结核患者咯血的叙述，正确的是A．大量咯血时多伴有胸痛B．约有1/2的患者有不同程度的咯血C．大量咯血主要是由于肺小动脉破裂D．痰中带血主要为病灶毛细血管扩张所致E．咯血后常伴有低热的原因主要是并发感染

单选题 对冻僵患者进行复温治疗，下列哪项措施最快? A、应用电热毯 B、输注加热液体 C、加热液体进行胃、直肠灌洗 D、血液透析 E、体外循环

单选题患者，男，52岁。患扩张型心肌病16年，呼吸困难、活动受限、下肢水肿4年，来院检查。查体：血压90／60 mmHg，心率96次/分，心律整，双肺底多数湿啰音，左心室舒张末内径69 mm，LVEF31％，尿蛋白微量，肾小球滤过率25 mL／min。此时对患者进行治疗，最合适的药物是( )(2008年)

单选题A．吸入激素加用吸入长效β 2 受体激动剂 B．吸入β 2 受体激动剂 C．皮下注射肾上腺素 D．静脉点滴氨茶碱 E．吸入异丙托溴胺下列患者如何选择药物治疗

单选题治疗亚急性感染性心内膜炎首选的抗菌药是

单选题A．原发性醛固酮增多症B．肾上腺皮质腺癌C．库欣综合征D．嗜铬细胞瘤

单选题17岁男性患者，双下肢水肿伴腹水，体重60kg，尿蛋白(＋＋＋＋)，m清白蛋白15g／L，用泼尼松60mg／d治疗7天，病情未见好转，尿蛋白仍(＋＋＋＋)。此时应采取下列哪项措施

单选题 亚铁离子从肠粘膜吸收的量，主要决定于以下哪种因素 A、与胃酸浓度有关 B、与体内维生素c含量有关 C、与体内铁贮存量有关 D、与身体铁排泄量有关 E、与食物中含铁多少有关

单选题男性，35岁，饮高度白酒450m1后第2天出现上腹及左上腹持续性疼痛、阵发性加重，并向腰背部放射，抱膝前屈位缓解，应首先考虑哪项诊断

单选题嗜肺军团菌肺炎的诊断依据之一是单次恢复期血清军团菌免疫荧光素标记抗体滴度为

单选题A．迷走一迷走反射B．肠．胃反射C．二者均有D．二者均无 (2002年)

单选题诊断反流性食管炎优先选择的检查方法是

单选题鉴别血尿与血红蛋白尿的最主要实验室检查是

单选题A．CD4受体B．CD8受体C．浆细胞D．巨噬细胞